Instil Bio Ends Development of Cancer Drug AXN-2510
Instil Bio's subsidiary Axion Bio discontinues clinical development of AXN-2510 and terminates collaboration agreement with ImmuneOnco, returning rights to the Chinese partner.
/ 1 item
#TIL↓